Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Rep ; 43(3): 113885, 2024 Mar 26.
Article in English | MEDLINE | ID: mdl-38457337

ABSTRACT

Amyotrophic lateral sclerosis damages proteostasis, affecting spinal and upper motor neurons earlier than a subset of cranial motor neurons. To aid disease understanding, we exposed induced cranial and spinal motor neurons (iCrMNs and iSpMNs) to proteotoxic stress, under which iCrMNs showed superior survival, quantifying the transcriptome and proteome for >8,200 genes at 0, 12, and 36 h. Two-thirds of the proteome showed cell-type differences. iSpMN-enriched proteins related to DNA/RNA metabolism, and iCrMN-enriched proteins acted in the endoplasmic reticulum (ER)/ER chaperone complex, tRNA aminoacylation, mitochondria, and the plasma/synaptic membrane, suggesting that iCrMNs expressed higher levels of proteins supporting proteostasis and neuronal function. When investigating the increased proteasome levels in iCrMNs, we showed that the activity of the 26S proteasome, but not of the 20S proteasome, was higher in iCrMNs than in iSpMNs, even after a stress-induced decrease. We identified Ublcp1 as an iCrMN-specific regulator of the nuclear 26S activity.


Subject(s)
Amyotrophic Lateral Sclerosis , Proteostasis , Humans , Proteostasis/physiology , Proteome/metabolism , Motor Neurons/metabolism , Amyotrophic Lateral Sclerosis/genetics , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum Stress
2.
ACS Omega ; 5(25): 15537-15546, 2020 Jun 30.
Article in English | MEDLINE | ID: mdl-32637829

ABSTRACT

The rise of single-cell transcriptomics has created an urgent need for similar approaches that use a minimal number of cells to quantify expression levels of proteins. We integrated and optimized multiple recent developments to establish a proteomics workflow to quantify proteins from as few as 1000 mammalian stem cells. The method uses chemical peptide labeling, does not require specific equipment other than cell lysis tools, and quantifies >2500 proteins with high reproducibility. We validated the method by comparing mouse embryonic stem cells and in vitro differentiated motor neurons. We identify differentially expressed proteins with small fold changes and a dynamic range in abundance similar to that of standard methods. Protein abundance measurements obtained with our protocol compared well to corresponding transcript abundance and to measurements using standard inputs. The protocol is also applicable to other systems, such as fluorescence-activated cell sorting (FACS)-purified cells from the tunicate Ciona. Therefore, we offer a straightforward and accurate method to acquire proteomics data from minimal input samples.

3.
Elife ; 82019 06 03.
Article in English | MEDLINE | ID: mdl-31157617

ABSTRACT

In amyotrophic lateral sclerosis (ALS) spinal motor neurons (SpMN) progressively degenerate while a subset of cranial motor neurons (CrMN) are spared until late stages of the disease. Using a rapid and efficient protocol to differentiate mouse embryonic stem cells (ESC) to SpMNs and CrMNs, we now report that ESC-derived CrMNs accumulate less human (h)SOD1 and insoluble p62 than SpMNs over time. ESC-derived CrMNs have higher proteasome activity to degrade misfolded proteins and are intrinsically more resistant to chemically-induced proteostatic stress than SpMNs. Chemical and genetic activation of the proteasome rescues SpMN sensitivity to proteostatic stress. In agreement, the hSOD1 G93A mouse model reveals that ALS-resistant CrMNs accumulate less insoluble hSOD1 and p62-containing inclusions than SpMNs. Primary-derived ALS-resistant CrMNs are also more resistant than SpMNs to proteostatic stress. Thus, an ESC-based platform has identified a superior capacity to maintain a healthy proteome as a possible mechanism to resist ALS-induced neurodegeneration.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Membrane Glycoproteins/genetics , Motor Neurons/metabolism , Neurons, Efferent/metabolism , Nuclear Pore Complex Proteins/genetics , Superoxide Dismutase-1/genetics , Amyotrophic Lateral Sclerosis/pathology , Amyotrophic Lateral Sclerosis/therapy , Animals , Cell Differentiation/genetics , Cranial Nerves , Disease Models, Animal , Humans , Mice , Mice, Transgenic , Motor Neurons/pathology , Mouse Embryonic Stem Cells/cytology , Mouse Embryonic Stem Cells/metabolism , Neurons, Efferent/drug effects , Spinal Cord/growth & development , Spinal Cord/pathology
4.
Neurobiol Aging ; 44: 9-21, 2016 08.
Article in English | MEDLINE | ID: mdl-27318130

ABSTRACT

Aging is accompanied by declines in memory performance, and particularly affects memories that rely on hippocampal-cortical systems, such as episodic and explicit. With aged populations significantly increasing, the need for preventing or rescuing memory deficits is pressing. However, effective treatments are lacking. Here, we show that the level of the mature form of insulin-like growth factor 2 (IGF-2), a peptide regulated in the hippocampus by learning, required for memory consolidation and a promoter of memory enhancement in young adult rodents, is significantly reduced in hippocampal synapses of aged rats. By contrast, the hippocampal level of the immature form proIGF-2 is increased, suggesting an aging-related deficit in IGF-2 processing. In agreement, aged compared to young adult rats are deficient in the activity of proprotein convertase 2, an enzyme that likely mediates IGF-2 posttranslational processing. Hippocampal administration of the recombinant, mature form of IGF-2 rescues hippocampal-dependent memory deficits and working memory impairment in aged rats. Thus, IGF-2 may represent a novel therapeutic avenue for preventing or reversing aging-related cognitive impairments.


Subject(s)
Aging/psychology , Insulin-Like Growth Factor II/administration & dosage , Insulin-Like Growth Factor II/physiology , Memory Disorders/etiology , Memory Disorders/prevention & control , Memory , Animals , Hippocampus/metabolism , Insulin-Like Growth Factor II/deficiency , Insulin-Like Growth Factor II/metabolism , Male , Memory, Short-Term , Molecular Targeted Therapy , Proprotein Convertase 2/metabolism , Protein Processing, Post-Translational , Rats , Rats, Inbred F344 , Recombinant Proteins/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...